[ad_1]
SINGAPORE – One of the two antibodies in the cocktail used to treat US President Donald Trump for COVID-19 was developed using blood samples from three patients in Singapore, according to a report by Asian Scientist magazine.
Trump had received a high dose of REGN-COV2 on Friday, a combination of two antibodies against the spike protein SARS-CoV-2 that causes COVID-19 disease, the report said Monday (October 5).
The combination was developed by the American biotech company Regeneron, which was able to clone the antibodies from both “humanized” mice and recovered COVID-19 patients to produce a reliable source of antibodies.
Asian Scientist reported that while the humanized mice were based on Regeneron’s proprietary technology, the human plasma used was supplied by three Singapore patients through an agreement with the country’s National Center for Infectious Diseases.
On September 29, Regeneron announced positive data from a phase one trial of 275 patients, showing that REGN-COV2 reduced viral levels and improved symptoms.
Trump had been administered the experimental therapy even though he had not received emergency use approval. It was administered under a compassionate use request, according to the report.
He was discharged from Walter Reed National Military Medical Center Monday night to return to the White House, three days after being admitted to the hospital for treatment for COVID-19 complications.
Lee Hsien Loong is ready to testify in a defamation lawsuit against Leong Sze Hian in High Court
Louis Ng vs Amy Khor: MPs debate proposed ban on smoking near HDB floor windows
Parliament: Bill to help smaller insolvent companies through faster and cheaper way of filing
Parliament: Security features of new ERP units are more superior to mobile phones – Amy Khor
